Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 May 2009

Chew Helen K, Doroshow James H, Frankel Paul, Margolin Kim A, Somlo George, Lenz Heinz-Josef, Gordon Michael, Zhang Wu, Yang Dongyun, Russell Christy, Spicer Darcy, Synold Tim, Bayer Robert, Hantel Alexander, Stiff Patrick J, Tetef Merry L, Gandara David R, Albain Kathy S

Abstract excerpt

PURPOSE: Cisplatin and gemcitabine have single-agent activity in metastatic breast cancer, and preclinical data support synergy of the combination. Two parallel, phase II trials were conducted to evaluate the response rate, response duration, and toxicities of the combination. Genetic polymorphisms were analyzed for correlation with outcomes. PATIENTS AND METHODS: Eligible women had measurable disease and heavily...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Cisplatin

Share to Deoxycytidine

Share to Gemcitabine

Share to Neoplasm Metastasis

Share to Polymorphism, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 19307510
DOI: 10.1200/JCO.2008.17.4839
PMCID: PMC2674003

Genes

XRCC3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.PMID 19307510Read ↗

Gemcitabine and platinum pathway pharmacogenetics in Asian breast cancer patients.Semantic proximity Read ↗

Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.Semantic proximity Read ↗

Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer.Semantic proximity Read ↗

Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).Semantic proximity Read ↗

Myelosuppression in a Metastatic Breast Cancer Patient with GSTP1 rs1695 Mutation Induced by Adriamycin and CyclophosphamideSemantic proximity Read ↗

Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).Semantic proximity Read ↗

Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer.Semantic proximity Read ↗

Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations.Semantic proximity Read ↗

A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies.Semantic proximity Read ↗

Palbociclib in endocrine-resistant metastatic breast cancer patients: gene polymorphism- based study.Semantic proximity Read ↗

An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients.Semantic proximity Read ↗

The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.